相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S]
Marianne G. Pouwer et al.
JOURNAL OF LIPID RESEARCH (2020)
ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model
Eva Hurt-Camejo
JOURNAL OF LIPID RESEARCH (2020)
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
N. S. Nurmohamed et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2020)
Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities
Kyriakos E. Kypreos et al.
ANGIOLOGY (2019)
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Theodosios D. Filippatos et al.
CURRENT VASCULAR PHARMACOLOGY (2019)
Therapeutic Antisense Oligonucleotides Are Coming of Age
C. Frank Bennett
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease
Julia Dittrich et al.
ATHEROSCLEROSIS (2019)
Lipid-Lowering Agents Targets Beyond PCSK9
Robert A. Hegele et al.
CIRCULATION RESEARCH (2019)
Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes
Eliza Christopoulou et al.
DISEASE MARKERS (2019)
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
Marja-Riitta Taskinen et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
Zahid Ahmad et al.
CIRCULATION (2019)
Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in US Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014
Wenjun Fan et al.
DIABETES CARE (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
Poulabi Banerjee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Elad Shemesh et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease
Yating Wang et al.
CLINICAL CARDIOLOGY (2019)
Apolipoprotein CIII and diabetes. Is there a link?
Eliza Christopoulou et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol
Yu-Xin Xu et al.
ATHEROSCLEROSIS (2018)
An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans
Adil Mardinoglu et al.
CELL METABOLISM (2018)
The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
Angela Pirillo et al.
CURRENT ATHEROSCLEROSIS REPORTS (2018)
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Nadia Bougarne et al.
ENDOCRINE REVIEWS (2018)
Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
Amirhossein Sahebkar et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES
Veronica J. Alexander et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2′-MOE-Modified Antisense Oligonucleotide
Padmakumar Narayanan et al.
TOXICOLOGICAL SCIENCES (2018)
Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation
Anna Cinkajzlova et al.
NUTRITION & DIABETES (2018)
Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials
Amirhossein Sahebkar et al.
ANNALS OF MEDICINE (2018)
The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study
Marcello Arca et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2018)
Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects
Maria Giovanna Lupo et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2018)
Changes in Low-density Lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions
Saulo Mendoza et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Apolipoprotein C-III Inhibition With Volanesorsen in Patients With Hypertriglyceridemia (COMPASS): A Randomized, Double-Blind, Placebo-Controlled Trial
Ioanna Gouni-Berthold et al.
Journal of Clinical Lipidology (2017)
The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
D. Gaudet et al.
Journal of Clinical Lipidology (2017)
Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity
Evangelia Zvintzou et al.
JOURNAL OF LIPID RESEARCH (2017)
Very-Low-Density Lipoprotein- Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
Raimund Pechlaner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
Nathan O. Stitziel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Angiopoietin-like 3 in lipoprotein metabolism
Sander Kersten
NATURE REVIEWS ENDOCRINOLOGY (2017)
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
F. E. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins
Patrick R. Lawler et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol
Patrick R. Lawler et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
Xun Chi et al.
MOLECULAR METABOLISM (2017)
SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY
Daniel Gaudet et al.
ATHEROSCLEROSIS (2017)
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Andres Digenio et al.
DIABETES CARE (2016)
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Alan Chait et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Philip L. S. M. Gordts et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Xiaohong Yang et al.
JOURNAL OF LIPID RESEARCH (2016)
The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
Mengdie Luo et al.
LIPIDS IN HEALTH AND DISEASE (2016)
The role of ANGPTL3 in controlling lipoprotein metabolism
Anna Tikka et al.
ENDOCRINE (2016)
Lomitapide
Sebastiaan C. Goulooze et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Yan Wang et al.
JOURNAL OF LIPID RESEARCH (2015)
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease
Alison B. Kohan
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2015)
Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation
Anna Tikka et al.
BIOSCIENCE REPORTS (2014)
Rare Variant APOC3 R19X Is Associated With Cardio-Protective Profiles in a Diverse Population-Based Survey as Part of the Epidemiologic Architecture for Genes Linked to Environment Study
Dana C. Crawford et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2014)
Effects of bariatric surgery on HDL structure and functionality: results from a prospective trial
Evangelia Zvintzou et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
HDL and cardiovascular disease
Daniel J. Rader et al.
LANCET (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Jacy Crosby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
Stanley T. Crooke et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
Mark J. Graham et al.
CIRCULATION RESEARCH (2013)
Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
Ilenia Minicocci et al.
JOURNAL OF LIPID RESEARCH (2013)
Qualitative characteristics of HDL in young patients of an acute myocardial infarction
Anthula E. Kavo et al.
ATHEROSCLEROSIS (2012)
The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease
Jamal S. Rana et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men
N. Faghihnia et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2012)
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Anastazia A. Kei et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia
Sandrine Caron et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation
O. Olivieri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients
E. S. Nakou et al.
LIPIDS (2010)
Mechanism of action of niacin
Vaijinath S. Kamanna et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial
Jeremy D. Furtado et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2008)
ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia
Kyriakos E. Kypreos
BIOCHEMISTRY (2008)
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Esther M. M. Ooi et al.
CLINICAL SCIENCE (2008)
Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome
Esther M. M. Ooi et al.
DIABETES CARE (2008)
Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome
Theodosios D. Filippatos et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2008)
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Toni I. Pollin et al.
SCIENCE (2008)
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia
Michael S. Kostapanos et al.
CLINICAL THERAPEUTICS (2007)
Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes
Lu Qi et al.
ATHEROSCLEROSIS (2007)
Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase
Mitsuru Shimamura et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappa B activation
Akio Kawakami et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells
Akio Kawakami et al.
CIRCULATION (2006)
The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk
CQ Lai et al.
CURRENT OPINION IN LIPIDOLOGY (2005)
Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice
I Duivenvoorden et al.
DIABETES (2005)
Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia
R Mar et al.
CIRCULATION RESEARCH (2004)
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
J Altomonte et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states
K Inukai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3) -: ANGPTL3 is cleaved and activated in vivo
M Ono et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Angptl3 regulates lipid metabolism in mice
R Koishi et al.
NATURE GENETICS (2002)
分享论文
